 |
 Video: What is a Stock Split?
|
|
|
| MediciNova is a biopharmaceutical company. Co. is focusing its development activities on MN-166 (ibudilast) for neurological and other disorders such as progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, substance dependence and addiction and prevention of acute respiratory distress syndrome, and MN-001 (tipelukast) for fibrotic diseases such as nonalcoholic steatohepatitis and idiopathic pulmonary fibrosis. Co.'s pipeline also includes MN-221 (bedoradrine) for the treatment of acute exacerbation of asthma and MN-029 (denibulin) for solid tumor cancers. According to our Medicinova stock split history records, Medicinova has had 0 splits. | |
|
Medicinova (MNOV) has 0 splits in our Medicinova stock split history database.
Looking at the Medicinova stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Medicinova shares, starting with a $10,000 purchase of MNOV, presented on a split-history-adjusted basis factoring in the complete Medicinova stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
| Start date: |
05/01/2014 |
|
| End date: |
04/29/2024 |
|
| Start price/share: |
$2.01 |
|
| End price/share: |
$1.29 |
|
| Dividends collected/share: |
$0.00 |
|
| Total return: |
-35.82% |
|
| Average Annual Total Return: |
-4.34% |
|
| Starting investment: |
$10,000.00 |
|
| Ending investment: |
$6,415.80 |
|
| Years: |
10.00 |
|
|
|
|
|
